These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26098609)

  • 1. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.
    van de Ven K; Borst J
    Immunotherapy; 2015; 7(6):655-67. PubMed ID: 26098609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting T Cell Co-receptors for Cancer Therapy.
    Callahan MK; Postow MA; Wolchok JD
    Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology.
    Nolte MA; van Olffen RW; van Gisbergen KP; van Lier RA
    Immunol Rev; 2009 May; 229(1):216-31. PubMed ID: 19426224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
    O'Neill RE; Cao X
    Adv Cancer Res; 2019; 143():145-194. PubMed ID: 31202358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).
    Starzer AM; Berghoff AS
    ESMO Open; 2020 Mar; 4(Suppl 3):e000629. PubMed ID: 32152062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.
    He LZ; Prostak N; Thomas LJ; Vitale L; Weidlick J; Crocker A; Pilsmaker CD; Round SM; Tutt A; Glennie MJ; Marsh H; Keler T
    J Immunol; 2013 Oct; 191(8):4174-83. PubMed ID: 24026078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation.
    Hintzen RQ; Lens SM; Lammers K; Kuiper H; Beckmann MP; van Lier RA
    J Immunol; 1995 Mar; 154(6):2612-23. PubMed ID: 7876536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CD70 for human therapeutic use.
    Boursalian TE; McEarchern JA; Law CL; Grewal IS
    Adv Exp Med Biol; 2009; 647():108-19. PubMed ID: 19760069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of CD70 and CD27.
    Wajant H
    Expert Opin Ther Targets; 2016 Aug; 20(8):959-73. PubMed ID: 26914723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
    Brunner-Weinzierl MC; Rudd CE
    Front Immunol; 2018; 9():2737. PubMed ID: 30542345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapy Targeting Co-signal Molecules.
    Nakajima M; Tamada K
    Adv Exp Med Biol; 2019; 1189():313-326. PubMed ID: 31758539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical deployment of antibodies for treatment of melanoma.
    Curti BD; Urba WJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):18-27. PubMed ID: 25746916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
    Mizuno R; Maruhashi T; Sugiura D; Shimizu K; Watada M; Okazaki IM; Okazaki T
    Biochem Biophys Res Commun; 2019 Apr; 511(3):491-497. PubMed ID: 30771904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer.
    Jacobs J; Zwaenepoel K; Rolfo C; Van den Bossche J; Deben C; Silence K; Hermans C; Smits E; Van Schil P; Lardon F; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 May; 6(15):13462-75. PubMed ID: 25951351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis.
    Oflazoglu E; Boursalian TE; Zeng W; Edwards AC; Duniho S; McEarchern JA; Law CL; Gerber HP; Grewal IS
    J Immunol; 2009 Sep; 183(6):3770-7. PubMed ID: 19710474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
    Waight JD; Gombos RB; Wilson NS
    Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.